Skip to main
BAX

Baxter (BAX) Stock Forecast & Price Target

Baxter (BAX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 67%
Sell 11%
Strong Sell 0%

Bulls say

Baxter International has demonstrated positive sales growth in its Healthcare Systems & Technologies segment, with increases of approximately 6% and 2% year-over-year in the first two quarters of 2025, and forecasts suggesting continued, albeit modest, growth of around 4% and 2% for the latter half of the year. The acquisition of Hillrom has expanded Baxter's operational portfolio, enhancing its range of hospital-focused products and strengthening its competitive position in the medical supplies industry. Furthermore, pricing initiatives are projected to contribute around 100 basis points to sales growth for 2024 and 2025, indicating effective management in boosting revenue amidst challenging market conditions.

Bears say

Baxter International's outlook is negatively impacted due to a disappointing performance in the second quarter of 2025, where sales, margins, and earnings per share fell below consensus expectations. The company has experienced a challenging operational period from 2021 to 2023, characterized by both external factors and internal missteps, resulting in mixed quarterly results and negative guidance revisions. Additionally, gross margins of 40.7% and operating margins of 15.1% fell short of consensus estimates, reflecting sales softness, manufacturing inefficiencies, and an unfavorable product mix.

Baxter (BAX) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Baxter (BAX) Forecast

Analysts have given Baxter (BAX) a Hold based on their latest research and market trends.

According to 9 analysts, Baxter (BAX) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Baxter (BAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.